학술논문

Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.
Document Type
journal article
Source
Journal of Clinical Oncology; 10/1/2017, Vol. 35 Issue 28, p3181-3188, 11p
Subject
Language
ISSN
0732183X